CLINICAL TRIALS PROFILE FOR NOVOSEVEN
✉ Email this page to a colleague
All Clinical Trials for NOVOSEVEN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00104455 ↗ | Dose Response to Recombinant Factor VIIa When Administered for Bleed | Completed | Novo Nordisk A/S | Phase 1 | 2004-06-01 | This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed. |
| NCT00108758 ↗ | Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia | Completed | Novo Nordisk A/S | Phase 2 | 2004-03-01 | This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors. |
| NCT00108797 ↗ | Trial of NovoSeven® in Haemophilia - Joint Bleeds | Completed | Novo Nordisk A/S | Phase 4 | 2001-09-01 | This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds. |
| NCT00123591 ↗ | Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury | Completed | Novo Nordisk A/S | Phase 2 | 2005-01-01 | This trial is conducted in Asia, Europe, Middle East, and North America. The primary objective of the trial is to evaluate the safety of Recombinant Activated Factor VII in patients with brain contusions. The secondary objective of the trial is to evaluate the preliminary efficacy of Recombinant Activated Factor VII in preventing early haemorrhagic progression in contusive brain injury. |
| NCT00127283 ↗ | Recombinant Factor VIIa in Acute Intracerebral Haemorrhage | Completed | Novo Nordisk A/S | Phase 3 | 2005-05-01 | This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America. The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding. |
| NCT00128050 ↗ | Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH) | Completed | IRCCS Policlinico S. Matteo | Phase 2 | 2005-01-01 | Although the role of surgical treatment is still controversial, surgical evacuation of intracerebral hematoma is a frequent practice. Rebleeding is a frequent complication in patients submitted to hematoma evacuation. It has been reported that smaller postoperative volume of hematoma is associated with a better outcome. The investigators hypothesize that the administration of Factor VIIa (Eptacog alfa) immediately after surgical evacuation of the hematoma can reduce postoperative rebleeding. Aims of the Study: This study will investigate: 1. The efficacy of Eptacog alfa in preventing or reducing rebleeding after surgery for spontaneous supratentorial ICH; and 2. The safety of product administration |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NOVOSEVEN
Condition Name
Clinical Trial Locations for NOVOSEVEN
Trials by Country
Clinical Trial Progress for NOVOSEVEN
Clinical Trial Phase
Clinical Trial Sponsors for NOVOSEVEN
Sponsor Name
